Antimicrobial treatment improves tryptophan metabolism and mood of patients with small intestinal bacterial overgrowth

Table 2 Urinary excretion of tryptophan and its metabolites in healthy subjects (group Control), and in patients with small intestinal bacterial overgrowth and with diarrhea-predominant (SIBO-D) or with constipation-predominant ( SIBO-C); average ± SD

Feature	Control	SIBO-D	SIBO-C	p
TRP (mg/gCr)	13.3 ± 2.30	12.2 ± 2.31	10.1 ± 1.22	< 0.001^b
5-HIAA (mg/gCr)	3.01 ± 0.39	3.89 ± 0.34	2.56 ± 0.64	< 0.05^a,c
5-HIAA/TRP	0.24 ± 0.01	0.32 ± 0.091	0.258 ± 0.016	< 0.01^a,c
KYN (mg/gCr)	0.45 ± 0.11	0.58 ± 0.13	0.83 ± 0.18	< 0.001^b,c
KYN/TRP	0.036 ± 0.011	0.04 ± 0.012	0.083 ± 0.023	< 0.001^b,c
XA (mg/gCr)	0.68 ± 0.27	0.81 ± 0.24	0.98 ± 0.25	< 0.05^a,b,c
QA (mg/gCr)	3.02 ± 0.99	4.17 ± 0.97	6.98 ± 0.94	< 0.05^a

TRP Tryptophan, 5-HIAA—5-hydroxyindoleacetic acid, KYN Kynurenine, XA Xanthurenic acid, QA Quinolinic acid, differences between groups: ^aControl vs SIBO-D, ^bControl vs SIBO-C, ^cSIBO-D vs SIBO-C

ISSN: 1743-7075